The RET/PTC3 oncogene activates classical NF-B by stabilizing NIK

Oncogene

Volumn 30, Issue 1, 2011, Pages 87-96

  Neely, R J ^a,b   Brose, M S ^a   Gray, C M ^a   McCorkell, K A ^a   Leibowitz, J M ^a   Ma, C ^a   Rothstein, J L ^b,c   May, M J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c AMGEN INC   (United States)

Author keywords

Hashimoto's thyroiditis; IKK; NF B; NIK; RET PTC; thyroid cancer

Indexed keywords

CXCL1 CHEMOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDE; PROTEIN RET; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; EMBRYO CELL; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; MUTANT; NONHUMAN; ONCOGENE RET; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STAINING;

ANIMALS; ENZYME STABILITY; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NF-KAPPA B; ONCOGENE PROTEINS, FUSION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-RET; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

MURINAE;

EID: 78650969389     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.396     Document Type: Article

References (43)

1. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. (2007). Frequent engagement of the classical and alternative NF-kB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130.
2. Basseres DS, Baldwin AS. (2006). NF-kB and IkB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817-6830.
3. Birbach A, Bailey ST, Ghosh S, Schmid JA. (2004). Cytosolic, nuclear and nucleolar localization signals determine subcellular distribution and activity of the NF-kB inducing kinase NIK. J Cell Sci 117: 3615-3624.
4. Borrello MG, Alberti L, Fischer A, Degl'innocenti D, Ferrario C, Gariboldi M et al. (2005). Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 102: 14825-14830.
5. Bunone G, Uggeri M, Mondellini P, Pierotti MA, Bongarzone I. (2000). RET receptor expression in thyroid follicular epithelial cell-derived tumors. Cancer Res 60: 2845-2849.
6. Ciampi R, Nikiforov YE. (2007). RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148: 936-941.
7. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C et al. (2002). The lymphotoxin-b receptor induces different patterns of gene expression via two NF-kB pathways. Immunity 17: 525-535.
8. Derudder E, Dejardin E, Pritchard LL, Green DR, Korner M, Baud V. (2003). RelB/p50 dimers are differentially regulated by tumor necrosis factor-a and lymphotoxin-b receptor activation: critical roles for p100. J Biol Chem 278: 23278-23284.
9. Eisenlohr LC, Rothstein JL. (2006). Oncogenic inflammation and autoimmune disease. Autoimmun Rev 6: 107-114.
10. Gilmore TD, Herscovitch M. (2006). Inhibitors of NF-kB signaling: 785 and counting. Oncogene 25: 6887-6899.
11. Hayashi H, Ichihara M, Iwashita T, Murakami H, Shimono Y, Kawai K et al. (2000). Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19: 4469-4475.
12. Hayden MS, Ghosh S. (2008). Shared principles in NF-kB signaling. Cell 132: 344-362.
13. He JQ, Saha SK, Kang JR, Zarnegar B, Cheng G. (2007). Specificity of TRAF3 in its negative regulation of the noncanonical NF-kB pathway. J Biol Chem 282: 3688-3694.
14. Karin M. (2006). NF-kB in cancer development and progression. Nature 441: 431-436.
15. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al.(2007). Promiscuous mutations activate the noncanonical NF-kB pathway in multiple myeloma. Cancer Cell 12: 131-144.
16. Lam LT, Davis RE, Ngo VN, Lenz G, Wright G, Xu W et al. (2008). Compensatory IKKa activation of classical NF-kB signaling during IKKb inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci USA 105: 20798-20803.
17. Lodyga M, De Falco V, Bai XH, Kapus A, Melillo RM, Santoro M et al. (2009). XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. Oncogene 28: 937-949.
18. Ludwig L, Kessler H, Wagner M, Hoang-Vu C, Dralle H, Adler G et al. (2001). NF-kB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res 61: 4526-4535.
19. Madge LA, Kluger MS, Orange JS, May MJ. (2008). Lymphotoxin-a1b2 and LIGHT induce classical and noncanonical NF-kB-dependent proinflammatory gene expression in vascular endothelial cells. J Immunol 180: 3467-3477.
20. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. (2000). Selective inhibition of NF-kB activation by a peptide that blocks the interaction of NEMO with the IkB kinase complex. Science 289: 1550-1554.
21. Monaco C, Visconti R, Barone MV, Pierantoni GM, Berlingieri MT, De Lorenzo C et al. (2001). The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane. Oncogene 20: 599-608.
22. Muzza M, Degl'innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S et al. (2009). The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol (Oxf) 72: 702-708.
23. Nellore A, Paziana K, Ma C, Tsygankova OM, Wang Y, Puttaswamy K et al. (2009). Loss of Rap1GAP in papillary thyroid cancer. J Clin Endocrinol Metab 94: 1026-1032.
24. Nibu K, Otsuki N, Nakao K, Sugasawa M, Rothstein JL. (2005). RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas. Eur Arch Otorhinolaryngol 262: 368-373.
25. Nishina T, Yamaguchi N, Gohda J, Semba K, Inoue J. (2009). NIK is involved in constitutive activation of the alternative NF-kB pathway and proliferation of pancreatic cancer cells. Biochem Biophys Res Commun 388: 96-101.
26. Pacifico F, Leonardi A. (2010). Role of NF-kB in thyroid cancer. Mol Cell Endocrinol 321: 29-35.
27. Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M et al. (2004). Oncogenic and anti-apoptotic activity of NF-kB in human thyroid carcinomas. J Biol Chem 279: 54610-54619.
28. Pufnock JS, Rothstein JL. (2009). Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. J Immunol 182: 5498-5506.
29. Razani B, Zarnegar B, Ytterberg AJ, Shiba T, Dempsey PW, Ware CF et al. (2010). Negative feedback in noncanonical NF-kB signaling modulates NIK stability through IKKa-mediated phosphorylation. Sci Signal 3: ra41.
30. Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G et al. (2006). RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab 91: 2414-2423.
31. Russell JP, Shinohara S, Melillo RM, Castellone MD, Santoro M, Rothstein JL. (2003). Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. Oncogene 22: 4569-4577.
32. Santoro M, Melillo RM, Grieco M, Berlingieri MT, Vecchio G, Fusco A. (1993). The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ 4: 77-84.
33. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G et al. (2001). Activation by IKKa of a second, evolutionary conserved, NF-kB signaling pathway. Science 293: 1495-1499.
34. Sheils OM, O'Eary JJ, Uhlmann V, Lattich K, Sweeney EC. (2000). RET/PTC-1 activation in Hashimoto thyroiditis. Int J Surg Pathol 8: 185-189.
35. Solt LA, Madge LA, Orange JS, May MJ. (2007). Interleukin-1-induced NF-kB activation is NEMO-dependent but does not require IKKb. J Biol Chem 282: 8724-8733.
36. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H et al. (2008). Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kB signaling. Nat Immunol 9: 1364-1370.
37. Veiga-Fernandes H, Coles MC, Foster KE, Patel A, Williams A, Natarajan D et al. (2007). Tyrosine kinase receptor RET is a key regulator of Peyer's patch organogenesis. Nature 446: 547-551.
38. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K et al. (1997). Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF-kB p65 protein expression. Oncogene 15: 1987-1994.
39. Wells Jr SA, Santoro M. (2009). Targeting the RET pathway in thyroid cancer. Clin Cancer Res 15: 7119-7123.
40. Wharry CE, Haines KM, Carroll RG, May MJ. (2009). Constitutive non-canonical NF-kB signaling in pancreatic cancer cells. Cancer Biol Ther 8: 1567-1576.
41. Wirtschafter A, Schmidt R, Rosen D, Kundu N, Santoro M, Fusco A et al. (1997). Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope 107: 95-100.
42. Xiao G, Harhaj EW, Sun SC. (2001). NF-kB-inducing kinase regulates the processing of NF-kB2 p100. Mol Cell 7: 401-409.
43. Zarnegar B, Yamazaki S, He JQ, Cheng G. (2008). Control of canonical NF-kB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci USA 105: 3503-3508.